These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 15728883

  • 1. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V, Hoover J, Singley C, Woodnutt G.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 3. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
    Torrico M, Aguilar L, González N, Giménez MJ, Echeverría O, Cafini F, Sevillano D, Alou L, Coronel P, Prieto J.
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3699-706. PubMed ID: 17664320
    [Abstract] [Full Text] [Related]

  • 4. Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.
    Alou L, Aguilar L, Sevillano D, Giménez MJ, González N, Echeverría O, Torrico M, Martín JE, Valdés L, Prieto J.
    J Chemother; 2007 Dec; 19(6):670-2. PubMed ID: 18230548
    [Abstract] [Full Text] [Related]

  • 5. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V, Thorburn CE, Knott SJ, Woodnutt G.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I, Cars O, Löwdin E.
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [Abstract] [Full Text] [Related]

  • 10. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 11. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.
    Koeth LM, Good CE, Saunders KA, Jakielaszek C.
    Int J Antimicrob Agents; 2004 Aug; 24(2):144-9. PubMed ID: 15288313
    [Abstract] [Full Text] [Related]

  • 12. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach.
    González N, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, Cafini F, Coronel P, Prieto J.
    J Antimicrob Chemother; 2009 Jun; 63(6):1215-22. PubMed ID: 19307171
    [Abstract] [Full Text] [Related]

  • 13. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ, Gimeno M, Coronel P.
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [Abstract] [Full Text] [Related]

  • 14. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
    MacGowan AP, Noel AR, Rogers CA, Bowker KE.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB, Ferguson B, Twynholm M, Wynne B, Berkowitz E, Poole MD.
    Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [Abstract] [Full Text] [Related]

  • 16. New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.
    Sánchez Navarro A.
    Clin Pharmacokinet; 2005 Aug; 44(11):1097-115. PubMed ID: 16231964
    [Abstract] [Full Text] [Related]

  • 17. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
    Hoberman A, Dagan R, Leibovitz E, Rosenblut A, Johnson CE, Huff A, Bandekar R, Wynne B.
    Pediatr Infect Dis J; 2005 Jun; 24(6):525-32. PubMed ID: 15933563
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ.
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [Abstract] [Full Text] [Related]

  • 20. Proof of concept: performance testing in models.
    Craig WA.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.